Stoke Therapeutics (NASDAQ:STOK) Posts Quarterly Earnings Results, Misses Expectations By $0.58 EPS

Stoke Therapeutics (NASDAQ:STOK) issued its quarterly earnings results on Wednesday. The company reported ($1.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.96) by ($0.58), Bloomberg Earnings reports.

Shares of NASDAQ:STOK traded up $0.40 during midday trading on Thursday, reaching $30.67. The company had a trading volume of 900 shares, compared to its average volume of 90,575. The stock has a 50 day simple moving average of $26.46. Stoke Therapeutics has a 52-week low of $22.01 and a 52-week high of $31.76.

A number of equities analysts recently weighed in on STOK shares. JPMorgan Chase & Co. started coverage on shares of Stoke Therapeutics in a report on Monday, July 15th. They issued an “overweight” rating and a $34.00 price target on the stock. Canaccord Genuity started coverage on shares of Stoke Therapeutics in a report on Monday, July 15th. They issued a “buy” rating and a $44.00 price target on the stock. Credit Suisse Group started coverage on shares of Stoke Therapeutics in a report on Monday, July 15th. They issued an “outperform” rating and a $35.00 price target on the stock. Finally, Cowen reissued a “buy” rating on shares of Stoke Therapeutics in a report on Thursday.



In related news, major shareholder Rtw Investments, Lp purchased 555,556 shares of the business’s stock in a transaction that occurred on Wednesday, June 19th. The shares were bought at an average cost of $18.00 per share, with a total value of $10,000,008.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder Apple Tree Partners Iv, L.P. purchased 1,388,889 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The stock was bought at an average cost of $18.00 per share, for a total transaction of $25,000,002.00. The disclosure for this purchase can be found here.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc has a partnership with Invitae Corporation to offer epilepsy panel testing.

See Also: What are the advantages to having securities held in street name?

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.